NIH funding uncertainty affects Bio-Techne guidance.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NIH funding uncertainty affects Bio-Techne guidance.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Sub-event
NIH funding uncertainty affects Bio-Techne guidance.1 source
Keep exploring
The entities involved
-
National Institutes of Health
government organization in Shah Alam, Malaysia
- The Trump administration seeks greater control over NIH grantmaking, while Susan Collins objects to the Office of Management and Budget's involvement.
- Binghamton University is receiving federal funding from the US Department of Energy and grants for advanced medical research from the National Institutes of Health.
-
Bio-Techne
company
Related events
- BioVie's candidate outperformed findings from an initiative led by the National Institutes of Health.
- Bio-Techne is facing scrutiny regarding its market performance and the growth of Protein Sciences, questioned by a UBS analyst.
- The National Institutes of Health (NIH) provided funding to a researcher at Worcester Polytechnic Institute (WPI).
- NIH cuts budgets and personnel, impacting funded research leading to FDA-approved treatments.
- The National Institutes of Health requires increased federal budget funding, with research demonstrating a potential $2.50 return on investment, discussed alongside U.S. Senator McCormick.
Coverage
Newest first; wire copies grouped- StockStoryTECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty Life sciences company Bio-Techne (NASDAQ:TECH) announced better-than-expected revenue in Q2 CY2025, with sales up 3.5%